SCHEMBL16285679

SCHEMBL16285679

Cc1ccccc1CCn1c(=O)ccc2ccc(Nc3ccc(N4CCN(C)CC4)cc3)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND3 P30281 8/20 0.46
CDK4 P11802 8/20 0.46
CCND1 P24385 8/20 0.46
CCND2 P30279 7/20 0.46
KDM1A O60341 2/20 0.42
ADRA2A P08913 3/20 0.41
ADRA2C P18825 3/20 0.41
ADRA2B P18089 2/20 0.41
JAK3 P52333 2/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
KIT P10721 1/20 0.41
SRC P12931 1/20 0.41
BRAF P15056 1/20 0.41
TYK2 P29597 1/20 0.41
KDR P35968 1/20 0.41
ZAP70 P43403 1/20 0.41
SYK P43405 1/20 0.41
MAPK10 P53779 1/20 0.41
TEK Q02763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16285672 0.91 CCND3 (0.47) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16285719 0.87 CDK4 (0.51) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16286134 0.87 PTK2 (0.46) CCND3CDK4CCND1CCND2ADRA2A
SCHEMBL16285700 0.82 CDK4 (0.46) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16285713 0.82 CDK4 (0.46) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16285692 0.82 CDK4 (0.46) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16285699 0.82 CDK4 (0.46) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16285681 0.82 FYN (0.56) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16285677 0.81 JAK2 (0.49) CCND3CDK4CCND1CCND2KDM1A
SCHEMBL16285684 0.81 CDK4 (0.45) CCND3CDK4CCND1CCND2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA AFRAXIS HOLDINGS INC (US) 2014-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA GRIN2A, GRIN2C, GRIN3A CCND3 4558/4885CDK4 2824/4885CCND1 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.